Skip to content

Different doses of topical finasteride in male AGA

Efficacy and safety of different doses of topical finasteride in the treatment of male androgenetic alopecia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240926001
Enrollment
80
Registered
2024-09-26
Start date
2024-05-29
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male androgenetic alopecia male androgenetic alopecia, pattern hair loss, topical finasteride

Interventions

0.5 - 1 ml (depending on the balding area) apply on the scalp twice daily for 24 weeks,0.5 - 1 ml (depending on the balding area) apply on the scalp twice daily for 24 weeks,0.5 - 1 ml (depending on t

Sponsors

Strategic Wisdom and Research Institute, Srinakharinwirot University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
25 Years to 60 Years

Inclusion criteria

Inclusion criteria: Androgenetic alopecia with mild to moderate severity

Exclusion criteria

Exclusion criteria: Allergic history to finasteride or minoxidil, use of topical medications for hair loss during previous 3 months, use of oral medications for hair loss during previous 6 months, use of light/laser therapy or PRP for hair loss during previous 3 months, hair transplantation, significant scalp diseases, history of depression or suicidal idea.

Design outcomes

Primary

MeasureTime frame
Change from baseline in hair density using videodermoscopy 24 weeks micrographs from videodermoscopy

Secondary

MeasureTime frame
Overall clinical changes from baseline 24 weeks paired global photographs,Change from baseline in serum DHT 24 weeks ELISA test for serum DHT,patient satisfaction 24 weeks 10-point visual analog scale,adverse events 24 weeks interview, questionnaire

Countries

Thailand

Contacts

Public ContactSaranya Khunkhet

Srinakharinwirot University

saranyakh@g.swu.ac.th0635691665

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026